Jazz Pharma director uses 1,855 shares for taxes

Q: What insider activity did Jazz Pharmaceuticals (JAZZ) disclose in this Form 4?

The filing reports that director Patrick Kennedy disposed of 1,855 Ordinary Shares on August 31, 2026 to satisfy tax obligations from the vesting of previously granted restricted stock units. No open-market purchases or sales were reported.

Q: How many Jazz Pharmaceuticals (JAZZ) shares were used to cover taxes?

A total of 1,855 Ordinary Shares were delivered or withheld to pay tax obligations. This comprised 15 shares at $244.0647 per share and 1,840 shares at $241.3900 per share, all on August 31, 2026.

Q: Was the Jazz Pharmaceuticals (JAZZ) insider transaction part of a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan; the document-level checkbox is not selected, and the only footnote explains that the shares were used to satisfy tax obligations from restricted stock unit vesting.

Q: Who is the reporting person in this Jazz Pharmaceuticals (JAZZ) Form 4 and what is their role?

The reporting person is Patrick Kennedy, identified in the filing as a director of Jazz Pharmaceuticals plc. The reported transactions relate to his equity compensation and associated tax obligations.

Jazz Pharmaceuticals plc (JAZZ) reported that director Patrick Kennedy disposed of shares in connection with equity compensation on August 31, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) reported that director Patrick Kennedy disposed of shares in connection with equity compensation on August 31, 2026. Two transactions used a total of 1,855 Ordinary Shares to pay tax obligations arising from the vesting of previously granted restricted stock units, with no open-market purchases or sales reported and no Rule 10b5-1 trading plan indicated.

Insider Trade Summary

Tax Withholding: 1,855 shares

Tax Withholding 2 txns

Insider Kennedy Patrick

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares ^F1	15	$244.0647	$4K
Tax Withholding	Ordinary Shares ^F1	1,840	$241.39	$444K

Holdings After Transaction: Ordinary Shares — 6,452 shares (Direct)

Footnotes (1)

F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Key Figures

Shares used to pay taxes (total): 1,855 shares Shares used to pay taxes (first transaction): 15 shares Shares used to pay taxes (second transaction): 1,840 shares +2 more

5 metrics

Shares used to pay taxes (total) 1,855 shares Ordinary Shares delivered or withheld on August 31, 2026 for tax obligations on RSU vesting

Shares used to pay taxes (first transaction) 15 shares Ordinary Shares on August 31, 2026 at $244.0647 per share, code F

Shares used to pay taxes (second transaction) 1,840 shares Ordinary Shares on August 31, 2026 at $241.3900 per share, code F

Price per share (first transaction) $244.0647 Used solely as a reference for 15-share tax-withholding disposition

Price per share (second transaction) $241.3900 Used solely as a reference for 1,840-share tax-withholding disposition

Key Terms

restricted stock units, vesting, tax obligations

3 terms

restricted stock units financial

"arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"tax obligations arising out of the vesting of previously granted restricted stock units"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

tax obligations financial

"Shares sold to satisfy tax obligations arising out of the vesting"

FAQ

What insider activity did Jazz Pharmaceuticals (JAZZ) disclose in this Form 4?

The filing reports that director Patrick Kennedy disposed of 1,855 Ordinary Shares on August 31, 2026 to satisfy tax obligations from the vesting of previously granted restricted stock units. No open-market purchases or sales were reported.

How many Jazz Pharmaceuticals (JAZZ) shares were used to cover taxes?

A total of 1,855 Ordinary Shares were delivered or withheld to pay tax obligations. This comprised 15 shares at $244.0647 per share and 1,840 shares at $241.3900 per share, all on August 31, 2026.

Was the Jazz Pharmaceuticals (JAZZ) insider transaction part of a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan; the document-level checkbox is not selected, and the only footnote explains that the shares were used to satisfy tax obligations from restricted stock unit vesting.

Did the Jazz Pharmaceuticals (JAZZ) director sell shares in the open market?

No open-market sales are reported. Both transactions are coded as F, described as payment of tax liability by delivering or withholding securities in connection with the vesting of restricted stock units, rather than discretionary market trades.

Who is the reporting person in this Jazz Pharmaceuticals (JAZZ) Form 4 and what is their role?

The reporting person is Patrick Kennedy, identified in the filing as a director of Jazz Pharmaceuticals plc. The reported transactions relate to his equity compensation and associated tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/02/2026 - 05:10 PM Accepted by SEC EDGAR 09/02/2026 - 05:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kennedy Patrick

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/31/2026		F⁽¹⁾		15	D	$244.0647	8,292	D
Ordinary Shares	08/31/2026		F⁽¹⁾		1,840	D	$241.39	6,452	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

	By: /s/Paz Dizon, as attorney in fact For: Patrick Kennedy	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR